Creo Medical Group (LON:CREO) Issues Quarterly Earnings Results

Creo Medical Group (LON:CREO) issued its earnings results on Wednesday. The company reported GBX (2) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Creo Medical Group had a negative return on equity of 38.29% and a negative net margin of 268.57%.

Creo Medical Group Price Performance

CREO stock opened at GBX 9.62 on Friday. The business has a fifty day moving average of GBX 12.62 and a two-hundred day moving average of GBX 12.82. The company has a quick ratio of 2.19, a current ratio of 2.79 and a debt-to-equity ratio of 8.09. The stock has a market cap of £46.72 million, a price-to-earnings ratio of 9.62 and a beta of 1.56. Creo Medical Group has a 52-week low of GBX 9.50 and a 52-week high of GBX 18.50.

Analysts Set New Price Targets

Separately, Shore Capital Group reissued a “house stock” rating and issued a GBX 40 price objective on shares of Creo Medical Group in a report on Thursday, July 23rd.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.